European patients with advanced EGFR mutation-positive non-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non- (EURTAC): a small-cell multicentre, open-label, randomised phase 3 trial.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non- ( EURTAC ) : a small-cell multicentre, open-label, randomised phase 3 trial .